Company: VERA
Filing Date: 2025-06-02
Form Type: 8-K
Source: 0001193125-25-132736
Chunk: 1

Company: Vera Therapeutics, Inc.
Filing Date: 2025-06-02
Form: 8-K
Item: Item 8.01
Chunk 1
---
Item 8.01      Other Events.  

As noted in Item 7.01, on June 2, 2025, the Company announced positive36-weekdata from the Company’s ORIGIN Phase 3 clinical trial of atacicept in adult patients with IgAN. Atacicept is the Company’s potential best-in-class, disease-modifyingdual inhibitor of the cytokines B-cellactivating factor and a proliferation-inducing ligand. ORIGIN Phase 3 is an ongoing global, multicenter, randomized, double-blind, placebo-controlled clinical trial of 431 adults evaluating the efficacy and safety of atacicept in adult patients with IgAN. The primary efficacy endpoint was the change in24-hoururine protein-to-creatinine ratio (“ UPCR”) compared to placebo at the36-weekinterim analysis.

Participants treated with atacicept (n=103) achieved a 46% reduction from baseline in proteinuria as measured by24-hourUPCR, with a statistically significant and clinically meaningful 42% reduction in UPCR compared to placebo (p<0.0001) at week 36. For other prespecified endpoints, atacicept treatment also demonstrated results that were consistent with or better than those previously observed in the ORIGIN Phase 2b trial. The safety profile of atacicept in this analysis was favorable, and comparable to placebo. The Company plans to share these results with the U. S. Food and Drug Administration (the “ FDA”) in the coming weeks, and full results will be submitted to the American Society of Nephrology Kidney Week.